I don't know what carrier you have but I can say it's time to re-apply and appeal. Here are the reasons that should make the a "no brainer".
1. Until this past week there was no published paper proving it was effective. But the CHAARTED trial now not only proves it effective in early settings, it also is now a liability to your carrier to deny it. You are however off protocol of CHAARTED as docetaxel was proven in that trial to be effective on initial application for HT in metastatic men with more extensive mets. But reason two is a good one:
2. Docetaxel is now a generic. It's not that big monster cost it used to be. And reason three is even better:
3. Should you become resistant to ADT, you are still not considered hormone refractory. There is always Xtandi and Zytiga. And they cost a hellofa lot more than 6 rounds of docetaxel. These options are still seeking when sequencing should take place but if docetaxel can delay them then the carriers stands to possibly pay less over time by approving chemotherapy in an earlier setting.
They listen to paying less. But whatever the plan, if your physician prescribes docetaxel and your carrier resists, then drafting them a letter that they are denying you access to prescribed cancer treatment can in fact be a liability under law and the threat of being reported to a state commission can soften their stance. Remember Todd's story. Kaiser denied his claims for Provenge in Washington and they lost on appeal.
Just a few thoughts here.